This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Two-Year Outcomes of the Five-Year SMART Trial, presented at CRT 2025. Reardon, M.D., Additional findings at five years include: Numerically lower rate of cardiovascular mortality (7.2%
The sociodemographic characteristics of patients undergoing intervention for aorticstenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.
Background Cardiogenic shock (CS) induced by severe aorticstenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain. Methods A systematic literature review and meta-analysis was performed.
IntroductionSince TAVR was approved for lower-risk aorticstenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV). Forty-seven received SEVs using COL, and 50 with CON techniques.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4
Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aorticstenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk. Original article: Thyregod HGH et al.
How does diffuse interstitial myocardial fibrosis, as observed on cardiac magnetic resonance (CMR), correlate with clinical outcomes in moderate and asymptomatic severe aorticstenosis (AS)?
BackgroundThe coexistence of transthyretin cardiac amyloidosis (ATTRCA) and aorticstenosis (AS) is increasingly recognized, but the clinical consequences are unclear. Ad hoc subanalyses were conducted in patients with aortic valve replacement at first diagnosis (surrogate for severe AS). 95% CI, 1.11.4];P<0.0001)
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aorticstenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Background A quarter of patients with severe aorticstenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aorticstenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
Valvular heart disease, including calcific or degenerative aorticstenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aorticstenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex. Specifically, 14.2%
Early detection through regular heart check-ups, including listening for murmurs, can lead to timely treatment and improved outcomes. The earlier we catch it, the more treatment options we have, and the better the outcome for the patient. AS occurs when the aortic valve narrows, restricting blood flow from the heart to the body.
(MedPage Today) -- People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aorticstenosis (AS) fared particularly poorly in a large cohort study, which researchers said calls for awareness and timely treatment. Compared with AS alone.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aorticstenosis (AS) and a small aortic annulus?
This concept should be applied when managing older patients with severe aorticstenosis. Although left ventricular wall hypertrophy is expected in patients with aorticstenosis, it should not be assumed that this is caused only by aorticstenosis.
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aorticstenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aorticstenosis. He then examines titration of medications after acute heart failure.
We aimed to quantify the impact of health system disruptions during the COVID-19 pandemic, on their clinical outcomes and whether these differed by socioeconomic and ethnic subgroups. Outcomes did not vary by pandemic birth era according to social characteristics.
Objective To use echocardiographic and clinical features to develop an explainable clinical risk prediction model in patients with aorticstenosis (AS), including those with low-gradient AS (LGAS), using machine learning (ML). for the combined outcome of mortality/AVR. p<0.05).
Some patients with aorticstenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. Circulation: Cardiovascular Interventions, Ahead of Print.
Patients with severe aorticstenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aortic valve replacement (AVR). The timing and magnit.
Bicuspid aortic valve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aorticstenosis and/or regurgitation, and is often associated with aortic root dilation.
What is the change in incidence, clinical presentation, treatment, and outcome for quantitatively defined severe aorticstenosis (AS) over the last 20 years in a population-based community?
BackgroundLp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown.
Among Medtronic's Structural Heart and Aortic key data milestones,Dr. The presentation addressed the two-year results of the SMall Annuli Randomized To Evolut or SAPIENTrial, which evaluated a valve performance in individuals with aortic stenosiswith small aortic annulusin patients treated with either EvolutTAVR platform or SAPIENplatform.
Aorticstenosis (AS) due to fibrosis and calcification of the aortic valve is a hazardous component of cardiovascular disease burden—after developing symptomatic AS, patients survive for an average of less than 2 years without treatment.
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aorticstenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Over a follow-up of up to 5 years, severe MR correlated with higher all-cause mortality (P=0.02) and aortic valve replacement rates (P=0.012).
What is the prevalence and what are the survival outcomes of patients with discordant high-gradient aorticstenosis (DHG-AS; defined as mean gradient [MG] ≥40 mm Hg and effective orifice area [EOA] >1.0
In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aorticstenosis.
BACKGROUND:Current guidelines recommend surgical aortic valve replacement (SAVR) for patients with severe aorticstenosis and unfavorable iliofemoral access. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).
Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aorticstenosis (AS). <aortic valve area (AVA)<1.5 <aortic valve area (AVA)<1.5 cm 2 , 3.0<peak
The goal of the NOTION trial was to compare outcomes after transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in unselected patients with severe degenerative aorticstenosis.
A new study demonstrates parity between a minimally invasive procedure to replace the aortic valve in the heart—transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR).
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aorticstenosis. 23), which was not associated with better/worse clinical outcomes in patients with prior CABG.
BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. Journal of the American Heart Association, Ahead of Print. In multivariate analysis, low CCDR (hazard ratio, 2.21 [95% CI, 0.99–4.92],P=0.04)
BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aorticstenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44];P=0.035). Poverall=0.765; 1 year: 1.4%
This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aortic valve solution that can be fit for the future, right from the start. 5 Verbelen T, Roussel JC, Cathenis K, et al.,
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content